Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The subcutaneous route of administration has provided convenient and non-inferior delivery of therapeutic proteins compared to intravenous infusion, but there is potential for enhanced immunogenicity toward subcutaneously administered proteins in a subset of patients. Unwanted anti-drug antibody response toward proteins or monoclonal antibodies upon repeated administration is shown to impact the pharmacokinetics and efficacy of multiple biologics. Unique immunogenicity challenges of the subcutaneous route have been realized through various preclinical and clinical examples, although subcutaneous delivery has often demonstrated comparable immunogenicity to intravenous administration. Beyond route of administration as a treatment-related factor of immunogenicity, certain product-related risk factors are particularly relevant to subcutaneously administered proteins. This review attempts to provide an overview of the mechanism of immune response toward proteins administered subcutaneously (subcutaneous proteins) and comments on product-related risk factors related to protein structure and stability, dosage form, and aggregation. A two-wave mechanism of antigen presentation in the immune response toward subcutaneous proteins is described, and interaction with dynamic antigen-presenting cells possessing high antigen processing efficiency and migratory activity may drive immunogenicity. Mitigation strategies for immunogenicity are discussed, including those in general use clinically and those currently in development. Mechanistic insights along with consideration of risk factors involved inspire theoretical strategies to provide antigen-specific, long-lasting effects for maintaining the safety and efficacy of therapeutic proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334
Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4
Termeer, C., Benedix, F., Sleeman, J., Fieber, C., Voith, U., Ahrens, T., Miyake, K., Freudenberg, M., Galanos, C., & Simon, J. C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20001858 · Cited by 1,378
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Structure and function of the immune system in the spleen
Lewis, S. M., Williams, A., & Eisenbarth, S. C. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau6085 · Cited by 1,301
CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions
Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Kiafard, Z., Zwirner, J., Blankenstein, T., Henning, G., & Förster, R. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.014 · Cited by 1,086
Wang, Y., Szretter, K. J., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., Barrow, A. D., Diamond, M. S., & Colonna, M. (2012) · Nature Immunology · doi:10.1038/ni.2360 · Cited by 1,011
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Supersaxo, A., Hein, W. R., & Steffen, H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015880819328 · Cited by 386
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Cited by
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.02.010 · Cited by 62
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
Albiges, L., Bourlon, M. T., Chacón, M., Cutuli, H. J., Chuken, Y. A. L., Żurawski, B., Mota, J. M., Magri, I., Burotto, M., Luz, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.002 · Cited by 31
Integrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399802 · Cited by 21
Metadata
- Authors
- Jarvi, N. L., & Balu-Iyer, S. V.
- Venue
- BioDrugs
- Published
- 2021-02-01
- Volume
- 35
- Issue
- 2
- Pages
- 125-146
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- OpenAlex
- W3127396319
- Cited by
- 105
- References
- 25
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins. https://app.cochat.ai/papers/10.1007/s40259-020-00465-4
- The paper
- Jarvi, N. L., & Balu-Iyer, S. V. (2021). Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins. BioDrugs. https://doi.org/10.1007/s40259-020-00465-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.